179 related articles for article (PubMed ID: 26273683)
1. BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients.
Lindberg U; Carlsson M; Hellmark T; Segelmark M
J Immunol Res; 2015; 2015():947934. PubMed ID: 26273683
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies.
Carlsson M; Eriksson L; Erwander I; Wieslander J; Segelmark M
Clin Exp Rheumatol; 2003; 21(6 Suppl 32):S95-100. PubMed ID: 14740434
[TBL] [Abstract][Full Text] [Related]
3. BPI-ANCA and long-term prognosis among 46 adult CF patients: a prospective 10-year follow-up study.
Lindberg U; Carlsson M; Löfdahl CG; Segelmark M
Clin Dev Immunol; 2012; 2012():370107. PubMed ID: 23346184
[TBL] [Abstract][Full Text] [Related]
4. Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis.
Carlsson M; Eriksson L; Pressler T; Kornfält R; Mared L; Meyer P; Wiik A; Wieslander J; Segelmark M
J Cyst Fibros; 2007 May; 6(3):228-33. PubMed ID: 17166780
[TBL] [Abstract][Full Text] [Related]
5. Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis.
Sedivá A; Bartůnková J; Kolárová I; Hrusák O; Vávrová V; Macek M; Lockwood CM; Dunn AC
J Autoimmun; 1998 Apr; 11(2):185-90. PubMed ID: 9650098
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas aeruginosa in cystic fibrosis: pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease.
Carlsson M; Shukla S; Petersson AC; Segelmark M; Hellmark T
J Cyst Fibros; 2011 Jul; 10(4):265-71. PubMed ID: 21463973
[TBL] [Abstract][Full Text] [Related]
7. Extensive endoscopic image-guided sinus surgery decreases BPI-ANCA in patients with cystic fibrosis.
Aanaes K; Rasmussen N; Pressler T; Segelmark M; Johansen HK; Lindberg U; Høiby N; Carlsson M; Wieslander J; Buchwald C
Scand J Immunol; 2012 Dec; 76(6):573-9. PubMed ID: 22946777
[TBL] [Abstract][Full Text] [Related]
8. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis.
Dorlöchter L; Carlsson M; Olafsdottir EJ; Røksund OD; Rosendahl K; Fluge G
J Cyst Fibros; 2004 Aug; 3(3):179-83. PubMed ID: 15463905
[TBL] [Abstract][Full Text] [Related]
9. Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease.
Mahadeva R; Dunn AC; Westerbeek RC; Sharples L; Whitehouse DB; Carroll NR; Ross-Russell RI; Webb AK; Bilton D; Lomas DA; Lockwood CM
Clin Exp Immunol; 1999 Sep; 117(3):561-7. PubMed ID: 10469063
[TBL] [Abstract][Full Text] [Related]
10. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.
Schultz H; Csernok E; Schuster A; Schmitz TS; Ernst M; Gross WL
Pediatr Allergy Immunol; 2000 May; 11(2):64-70. PubMed ID: 10893006
[TBL] [Abstract][Full Text] [Related]
11. BPI-ANCA is expressed in the airways of cystic fibrosis patients and correlates to platelet numbers and Pseudomonas aeruginosa colonization.
Hovold G; Lindberg U; Ljungberg JK; Shannon O; Påhlman LI
Respir Med; 2020; 170():105994. PubMed ID: 32843162
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis.
Lachenal F; Nkana K; Nove-Josserand R; Fabien N; Durieu I
Eur Respir J; 2009 Nov; 34(5):1079-85. PubMed ID: 19443536
[TBL] [Abstract][Full Text] [Related]
13. BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro.
Schultz H; Schinke S; Mosler K; Herlyn K; Schuster A; Gross WL
Pediatr Pulmonol; 2004 Feb; 37(2):158-64. PubMed ID: 14730661
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.
Zhao MH; Jayne DR; Ardiles LG; Culley F; Hodson ME; Lockwood CM
QJM; 1996 Apr; 89(4):259-65. PubMed ID: 8733512
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin.
Rotschild M; Elias N; Berkowitz D; Pollak S; Shinawi M; Beck R; Bentur L
Clin Exp Med; 2005 Jul; 5(2):80-5. PubMed ID: 16096858
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies directed against bactericidal/permeability-increasing protein in patients with cystic fibrosis: association with microbial respiratory tract colonization.
Aebi C; Theiler F; Aebischer CC; Schoeni MH
Pediatr Infect Dis J; 2000 Mar; 19(3):207-12. PubMed ID: 10749460
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of systemic and mucosal autoimmunity in cystic fibrosis.
Theprungsirikul J; Skopelja-Gardner S; Meagher RE; Clancy JP; Zemanick ET; Ashare A; Rigby WFC
J Cyst Fibros; 2020 Mar; 19(2):196-202. PubMed ID: 31262645
[TBL] [Abstract][Full Text] [Related]
18. Antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein detected in children with cystic fibrosis inhibit neutrophil-mediated killing of Pseudomonas aeruginosa.
Sedivá A; Bartůnková J; Bartosová J; Jennette C; Falk RJ; Jethwa HS
Microbes Infect; 2003 Jan; 5(1):27-30. PubMed ID: 12593970
[TBL] [Abstract][Full Text] [Related]
19. Scorpionfish BPI is highly active against multiple drug-resistant
Holzinger JM; Toelge M; Werner M; Ederer KU; Siegmund HI; Peterhoff D; Blaas SH; Gisch N; Brochhausen C; Gessner A; Bülow S
Elife; 2023 Jul; 12():. PubMed ID: 37461324
[TBL] [Abstract][Full Text] [Related]
20. Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.
Aichele D; Schnare M; Saake M; Röllinghoff M; Gessner A
Infect Immun; 2006 Aug; 74(8):4708-14. PubMed ID: 16861658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
